Clinical Trials

This will be a prospective registry conducted and maintained at Mayo Clinic Rochester from which collaborating sites within Mayo, Mayo Health Systems, and other spinal cord injury centers can draw from in order to fulfill research enrollment. The information collected for this registry will be used for recruitment purposes only, and will not be used as research data. Participants who are recruited to participate in other research studies will need to complete a separate consenting/enrollment process specific to that study.

The purpose of this study is to determine whether meeting the physical activity guidelines for cardiometabolic health is associated with positive health-related outcomes.

Additionally to determine whether meeting the physical activity guidelines for cardiometabolic health is associated with positive psychosocial outcomes, and determine whether meeting the physical activity guidelines for cardiometabolic health is associated with greater social and occupational integration.  

This is a survey study to identify user-reported motor, sensory, and autonomic functions that are enabled by epidural stimulation, establish correlations between epidural stimulation usage, rehabilitation, functional gains, and user experience in the laboratory and community settings, and to understand and identify subjective goals, benefits, and barriers that still exist with implanted epidural stimulator community.

A study to compare electrophysiologic activity of epidural stimulation and dorsal root ganglion stimulation, as well as quantify changes in motor performance with both types of stimulation over the course of 10 rehabilitation sessions.

The purpose of this study is to determine the rate at which patients who underwent Spinal Cord Stimulation (SCS) trial ultimately progressed to SCS implantation, determine the percentage of patients who continued using their SCS system after 5 years, as well as identify patient characteristics that lead to SCS discontinuation.

The proposed study is intended to inform the hypotheses that (1) regular dosing of exoskeleton walking will provide health benefits to non-ambulatory and poorly-ambulatory individuals with SCI, including decreased pain and spasticity, improvements in bowel and bladder function, decreased body-mass index (BMI), enhanced well-being; (2) regular dosing of exoskeleton walking will facilitate neurological or functional recovery in some individuals with SCI, particularly those with incomplete injuries; and (3) the level of mobility enabled by a lower limb exoskeleton is commensurate with the walking speeds, distances, and surfaces required for community ambulation.